In a recent paper, Somiari and Somiari offered insight into the requirements for future biobanking, focusing on a research-ready hospital RRH model and recommendations for enhanced sustainability. The authors indicate that future biobanking strategies will need to prioritize affordable, on-demand biospecimen acquisition.
These strategies must provide:. The authors offer the RRH conceptual model as a novel response to these requirements. According to the authors, a functioning RRH should be able to meet administrative, technical and regulatory requirements; provide multiple types of samples; store biospecimens short term; and transport samples to end users or centralized biobanks for long-term storage. The authors indicate that a project of this scope will require considerable partnership, ideally across both the public and private sector.
Further to this, the RRH hospitals must be recognized as true partners rather than mere suppliers, requiring clearly defined intellectual property rights. Somiari and Somiari suggest this division of responsibilities:. Notably, this RRH model would allow the scientific community to access biospecimens acquired from rural hospitals, an as yet underutilized source. Ultimately, greater access via RRH partnerships could improve translational medicine, including the search for novel biomarkers and drug development.
Future biobanks will also need to address sustainability issues, increasing supply value while minimizing storage and distribution costs. The authors offer this model grading system for ranking biospecimens in order to objectively weigh the value and cost of particular specimens:. Further to this, the team recommends tightened protocols for the distribution of required samples only e.
This would reduce space requirements, energy usage and operations costs. As the requirements of translational medicine and the various related -omics research fields place novel demands on the biobanking system, flexible responses like those presented here by Somiari and Somiari may be key to preserving and extending the impact of the biobanking industry. Somiari, S. Your email address will not be published. These strategies must provide: Greater numbers of samples A wide variety of biospecimens Samples pertaining to rare diseases and conditions Increased centers for procuring samples Sustainability The authors offer the RRH conceptual model as a novel response to these requirements.
Somiari and Somiari suggest this division of responsibilities: Technical and operational biobanking activities should be overseen by an established, College of American Pathologists CAP -accredited biobanking organization. The coordinating biobank should train hospital staff on standard operating procedures SOPs related to sample collection, storage and distribution.
Each member hospital should maintain its own quality assurance using coordinated SOPs. RRH staff should also receive specific training on recognizing rare conditions to ensure the acquisition of relevant samples. The overseeing biobank should maintain communication with researchers and coordinate sample collection and distribution; a secondary workflow funneling unclaimed samples from the RRH to the biobank should also operate. The authors offer this model grading system for ranking biospecimens in order to objectively weigh the value and cost of particular specimens: Table: Conceptual Grading System 1 Grade Description Value Note 1 No clinical annotation.
Molly Courtenay. Pharmaceutical Toxicology in Practice. Alberto Lodola. Pharmaceutical Medicine. Adrian Kilcoyne. Debora Simmons.
Flow Cytometry in Drug Discovery and Development. Virginia Litwin. Sajeesh Kumar. Pharmacy Student Survival Guide, 3E. Michelle T. Cancer on Trial. Peter Keating. Stem Cell Banking. Dusko Ilic. Attrition in the Pharmaceutical Industry. Alexander Alex.
Rare Diseases in the Age of Health 2. Rajeev K. Brian L. Medication Management in Older Adults. Susan Koch. Advances in Applied Microbiology. Geoffrey M. Pediatric Drug Development.
tensorflow.embedded-vision.com/yosemite-presin-de-pdf-de-manual.php Andrew E. Orphan Drugs. Practical Prescribing for Medical Students. Mrs Helen Bradbury. Independent and Supplementary Prescribing. Brian Jacobs. The Textbook of Pharmaceutical Medicine. John P.
Global New Drug Development. Jan A. Key Topics in Surgical Research and Methodology. Thanos Athanasiou. Genomic and Personalized Medicine.
Geoffrey S. Translational Medicine and Drug Discovery. Bruce H. Textbook of Pharmacoepidemiology. Advances in Pharmaceutical Cell Therapy. Natan Gadoth. Frederick P Ognibene. Cell Therapy. Rakesh Biswas. Biomedical Research. Computer-Assisted Musculoskeletal Surgery. Lucas E. Of Fish, Fly, Worm, and Man.
Athina Lazakidou. Translational Stem Cell Research. Atsushi Kumanogoh. Methods in Endothelial Cell Biology. Hellmut G. Essentials of Genomic and Personalized Medicine. Annual Review of Nursing Research, Volume 29, Ginette A.
Fluorescent Proteins I. Gregor Jung. Drug Discovery Toxicology. Eric McDuffie. Rodrigo R. Novel Psychoactive Substances. Paul Dargan. D-type Cyclins and Cancer. Nelson E. Value Creation in the Pharmaceutical Industry. Alexander Schuhmacher. Chromosomal Translocations and Genome Rearrangements in Cancer. Janet D. Chembiomolecular Science. Masakatsu Shibasaki. Carole Farrell. BeadChip Molecular Immunohematology. JoAnn M. Cell Fusion in Health and Disease. Thomas Dittmar. Analytical Chemistry for Assessing Medication Adherence.
Advances in Nuclear Architecture. Niall M. Sanetaka Shirahata.
Cord Blood Stem Cells Medicine. Catherine Stavropoulos-Giokas. Mechanisms of Molecular Carcinogenesis — Volume 2. Johannes Haybaeck. Stem Cells in Regenerative Medicine. Alain A. Microbial Biochemistry. Progress and Challenges in Precision Medicine.